Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · IEX Real-Time Price · USD
7.19
-0.44 (-5.77%)
Aug 11, 2022 4:00 PM EDT - Market closed
-5.77%
Market Cap 1.78B
Revenue (ttm) 41.87M
Net Income (ttm) -237.05M
Shares Out 247.83M
EPS (ttm) 1.67
PE Ratio 4.31
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 465,300
Open 7.66
Previous Close 7.63
Day's Range 7.14 - 7.69
52-Week Range 3.57 - 19.84
Beta n/a
Analysts Buy
Price Target 14.62 (+103.3%)
Earnings Date Aug 11, 2022

About LYEL

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that tar... [Read more...]

Industry Biotechnology
IPO Date Jun 17, 2021
Employees 219
Stock Exchange NASDAQ
Ticker Symbol LYEL
Full Company Profile

Financial Performance

In 2021, LYEL's revenue was $10.65 million, an increase of 37.31% compared to the previous year's $7.76 million. Losses were -$250.22 million, 22.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for LYEL stock is "Buy." The 12-month stock price forecast is 14.62, which is an increase of 103.34% from the latest price.

Price Target
$14.62
(103.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therap...

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' barga...

Other symbols: BBCDAWNKZRMRTXRPTX

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for...

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tum...

Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 341%: Here's is How to Trade

The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 341.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Mee...

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tum...

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid t...

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2...

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...

Biotech IPOs Have Slowed to a Snail's Pace

Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies raise...

Other symbols: SANA

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tu...

FDA Clears Lyell Immunopharma' LYL132 Trial For Solid Tumors

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell recepto...

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Develo...

LYL132 is an NY-ESO-1-targeted TCR therapy that incorporates Epi-R™, Lyell's novel epigenetic reprogramming technology designed to create populations of T cells with properties of durable stemness LYL13...

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramm...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma , Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...

Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with...

Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

Lyell Immunopharma shares fall in trading debut

Shares of San Francisco-based Lyell Immunopharma Inc. , a clinical-stage biotech that is developing T cell therapies for solid tumors, stumbled in their trading debut Thursday, falling 2.2% at last chec...

3 Biotechs Plus a Mortgage Lender Go Public Today

The companies are Verve Therapeutics, Lyell Immunopharma, iSpecimen and Angel Oak Mortgage.

Other symbols: VERVISPC

Lyell Immunopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...